Coastar Therapeutics, Inc.
Coastar Therapeutics is a San Diego-based biotech company dedicated to developing biological payload delivery technologies for cancer and gene therapies. Their proprietary ENHEnSTM technology coats cell membranes on biological payloads to evade immune recognition and deliver to disease sites, aiming to improve efficacy, reduce toxicity, and lower treatment costs. The company is actively involved in advancing gene and cell therapy delivery systems, collaborating with global partners, and participating in industry conferences to showcase their innovative solutions.
Industries
Nr. of Employees
small (1-50)
Coastar Therapeutics, Inc.
9520 Padgett Street Suite 101, San Diego, CA 92126, United States
Patents
Products
Erythrocyte-derived membrane nanocarrier platform
A platform that uses erythrocyte-derived cell membranes to coat biological payloads, intended to reduce immune clearance and enable targeted delivery of therapeutics.
Erythrocyte-derived membrane nanocarrier platform
A platform that uses erythrocyte-derived cell membranes to coat biological payloads, intended to reduce immune clearance and enable targeted delivery of therapeutics.
Services
Co-development and licensing collaborations to apply membrane-derived delivery technologies to partner therapeutic programs (viral and non-viral payloads).
Design, qualification, and transfer of cellular and enzyme-based bioassays and QC-suitable analytical methods to support in-process control, release testing, and pilot process development.
Optimization and scale-up of processes for membrane-material production and biologic payloads, including pilot-scale process development and technical transfer to manufacturing partners.
Support for cGMP-compliant operations including equipment commissioning, troubleshooting, validation support, and preparation for regulatory audits.
Generation of preclinical efficacy and safety data and coordination of studies necessary to advance therapeutic candidates toward IND-enabling packages.
Co-development and licensing collaborations to apply membrane-derived delivery technologies to partner therapeutic programs (viral and non-viral payloads).
Design, qualification, and transfer of cellular and enzyme-based bioassays and QC-suitable analytical methods to support in-process control, release testing, and pilot process development.
Optimization and scale-up of processes for membrane-material production and biologic payloads, including pilot-scale process development and technical transfer to manufacturing partners.
Support for cGMP-compliant operations including equipment commissioning, troubleshooting, validation support, and preparation for regulatory audits.
Generation of preclinical efficacy and safety data and coordination of studies necessary to advance therapeutic candidates toward IND-enabling packages.
Expertise Areas
- Gene delivery and nanocarrier platforms
- Oncolytic virotherapy delivery
- Viral vector (AAV, lentivirus) production and characterization
- In vivo and in vitro genome-editing delivery
Key Technologies
- Erythrocyte-derived membrane nanocarriers (cell membrane coating)
- Oncolytic virus delivery
- AAV vector delivery
- Lentiviral transduction and production
News & Updates
The company announced its participation at the BIO International Convention, June 13-16, 2022, where it showcased its innovative delivery technology.
On June 30, 2021, Coastar announced the successful closing of its seed funding round to accelerate R&D programs.
On October 1, 2024, Coastar announced its participation in JLABS, an early-stage biotech accelerator of Johnson & Johnson.
On November 5, 2024, Coastar was nominated for the prestigious Prix Galien USA Award, recognizing excellence in biotech innovation.
The company announced its participation at the BIO International Convention, June 13-16, 2022, where it showcased its innovative delivery technology.
On June 30, 2021, Coastar announced the successful closing of its seed funding round to accelerate R&D programs.
On October 1, 2024, Coastar announced its participation in JLABS, an early-stage biotech accelerator of Johnson & Johnson.
On November 5, 2024, Coastar was nominated for the prestigious Prix Galien USA Award, recognizing excellence in biotech innovation.